Eurobio Scientific SA
PAR:ALERS
Eurobio Scientific SA
Cash from Operating Activities
Eurobio Scientific SA
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Cash from Operating Activities
€23.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Cash from Operating Activities
-€67.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
|
Nanobiotix SA
PAR:NANO
|
Cash from Operating Activities
-€1m
|
CAGR 3-Years
67%
|
CAGR 5-Years
50%
|
CAGR 10-Years
18%
|
|
|
Innate Pharma SA
PAR:IPH
|
Cash from Operating Activities
-€18.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-4%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Cash from Operating Activities
-€41.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-12%
|
|
|
Inventiva SA
PAR:IVA
|
Cash from Operating Activities
-€84.7m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Eurobio Scientific SA
Glance View
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
See Also
What is Eurobio Scientific SA's Cash from Operating Activities?
Cash from Operating Activities
23.1m
EUR
Based on the financial report for Jun 30, 2024, Eurobio Scientific SA's Cash from Operating Activities amounts to 23.1m EUR.
What is Eurobio Scientific SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
63%
Over the last year, the Cash from Operating Activities growth was -20%. The average annual Cash from Operating Activities growth rates for Eurobio Scientific SA have been -35% over the past three years , 63% over the past five years .
You don't have any saved screeners yet